Lifecore Current Deferred Revenue vs Short Long Term Debt Analysis
LFCR Stock | 5.94 0.07 1.19% |
Lifecore Biomedical financial indicator trend analysis is infinitely more than just investigating Lifecore Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lifecore Biomedical is a good investment. Please check the relationship between Lifecore Biomedical Current Deferred Revenue and its Short Long Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.
Current Deferred Revenue vs Short Long Term Debt
Current Deferred Revenue vs Short Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lifecore Biomedical Current Deferred Revenue account and Short Long Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Lifecore Biomedical's Current Deferred Revenue and Short Long Term Debt is -0.03. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Lifecore Biomedical, assuming nothing else is changed. The correlation between historical values of Lifecore Biomedical's Current Deferred Revenue and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Lifecore Biomedical are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Current Deferred Revenue i.e., Lifecore Biomedical's Current Deferred Revenue and Short Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.03 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Most indicators from Lifecore Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Selling General Administrative is relatively stable compared to the past year. As of 05/21/2024, Tax Provision is likely to grow to about 363.5 K, while Enterprise Value Over EBITDA is likely to drop 7.98.
2021 | 2023 | 2024 (projected) | Total Revenue | 185.8M | 213.7M | 323.1M | Interest Expense | 17.4M | 19.9M | 20.8M |
Lifecore Biomedical fundamental ratios Correlations
Click cells to compare fundamentals
Lifecore Biomedical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lifecore Biomedical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 541.3M | 502.9M | 295.2M | 295.4M | 339.8M | 246.8M | |
Short Long Term Debt Total | 221.1M | 221.4M | 153.2M | 153.1M | 176.1M | 184.9M | |
Other Current Liab | 19.0M | 20.3M | 16.9M | 17.1M | 19.6M | 12.6M | |
Total Current Liabilities | 164.4M | 101.9M | 79.2M | 79.4M | 91.3M | 55.4M | |
Total Stockholder Equity | 231.0M | 202.8M | 107.9M | 108.1M | 124.4M | 139.4M | |
Property Plant And Equipment Net | 200.0M | 217.7M | 200.4M | 139.0M | 159.9M | 167.9M | |
Net Debt | 220.8M | 220.1M | 151.5M | 151.4M | 174.2M | 182.9M | |
Retained Earnings | 71.2M | 38.6M | (58.9M) | (58.7M) | (67.5M) | (64.1M) | |
Accounts Payable | 54.0M | 51.6M | 47.6M | 15.8M | 18.2M | 23.5M | |
Cash | 1.1M | 360K | 1.3M | 1.6M | 1.5M | 1.4M | |
Non Current Assets Total | 386.1M | 384.2M | 354.6M | 171.4M | 197.2M | 160.7M | |
Non Currrent Assets Other | (9.7M) | (25.3M) | (26.7M) | 3.0M | 2.7M | 2.8M | |
Cash And Short Term Investments | 1.1M | 360K | 1.3M | 1.6M | 1.5M | 1.4M | |
Common Stock Shares Outstanding | 29.2M | 29.3M | 29.5M | 29.5M | 33.9M | 25.9M | |
Liabilities And Stockholders Equity | 541.3M | 502.9M | 295.2M | 295.4M | 339.8M | 246.8M | |
Non Current Liabilities Total | 145.9M | 198.3M | 108.0M | 107.9M | 124.1M | 130.3M | |
Inventory | 66.3M | 69.7M | 66.8M | 67.0M | 77.0M | 80.9M | |
Other Current Assets | 8.3M | 14.2M | 7.4M | 7.1M | 6.3M | 9.0M | |
Other Stockholder Equity | 160.3M | 162.6M | 165.5M | 167.4M | 192.5M | 118.6M | |
Total Liab | 310.3M | 300.1M | 187.2M | 187.3M | 215.4M | 226.2M | |
Total Current Assets | 157.1M | 148.3M | 123.7M | 124.0M | 142.6M | 86.1M | |
Short Term Debt | 61.8M | 93.4M | 32.9M | 45.6M | 52.5M | 55.1M | |
Net Receivables | 76.2M | 70.0M | 48.2M | 48.3M | 55.6M | 35.4M | |
Intangible Assets | 45.2M | 38.1M | 36.1M | 15.6M | 17.9M | 17.0M | |
Current Deferred Revenue | 499K | 352K | 1.1M | 919K | 827.1K | 1.3M | |
Good Will | 54.5M | 76.7M | 69.4M | 13.9M | 16.0M | 15.2M | |
Accumulated Other Comprehensive Income | 64K | (2.8M) | (1.4M) | (586K) | (527.4K) | (553.8K) | |
Other Liab | 14.6M | 11.3M | 422K | 3.5M | 3.1M | 3.0M | |
Net Tangible Assets | 123.6M | 143.2M | 78.5M | (19.9M) | (17.9M) | (17.0M) | |
Other Assets | 2.2M | 157.7M | 3.0M | 3.2M | 3.7M | 3.5M | |
Long Term Debt | 101.4M | 164.9M | 97.6M | 101.3M | 116.5M | 121.5M | |
Capital Lease Obligations | 30.8M | 27.5M | 15.0M | 11.0M | 9.9M | 14.1M | |
Net Invested Capital | 421.4M | 396.7M | 246.1M | 99.9M | 89.9M | 85.4M | |
Short Long Term Debt | 89.0M | 29M | 40.6M | 488K | 439.2K | 417.2K | |
Non Current Liabilities Other | 4.6M | 3.6M | 190K | 3.1M | 2.8M | 2.1M | |
Net Working Capital | (7.3M) | 46.4M | 44.5M | 60.5M | 69.6M | 73.0M | |
Property Plant Equipment | 217.7M | 137.4M | 139.0M | 134.6M | 121.1M | 132.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.Note that the Lifecore Biomedical information on this page should be used as a complementary analysis to other Lifecore Biomedical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Lifecore Stock analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Lifecore Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lifecore Biomedical. If investors know Lifecore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lifecore Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 3.447 | Quarterly Revenue Growth 0.208 | Return On Assets (0.05) | Return On Equity (1.05) |
The market value of Lifecore Biomedical is measured differently than its book value, which is the value of Lifecore that is recorded on the company's balance sheet. Investors also form their own opinion of Lifecore Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Lifecore Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lifecore Biomedical's market value can be influenced by many factors that don't directly affect Lifecore Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lifecore Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lifecore Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lifecore Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.